<br/>The Challenges Most Face

Contamination Control Strategy

Creating a Holistic Contamination Control Strategy (CCS)

You need to be able to monitor and reduce particulates and microbiological contaminants, assure sterility and work towards the use of barrier technologies. Are you ready to implement these changes?

Container Closure Integrity

Effectively Maintaining Container Closure Integrity (CCI)

You need to have a robust understanding of the factors impacting CCI so that you can monitor and test each factor over the life of the drug product. Are your processes set up to do this?

Extractables and Leachables

Extractables and Leachables (E&L) is a New Inclusion

E&L have both direct and indirect impacts on product quality and patient safety as the extractable could be toxic and impurities could interact with the drug product. How will you manage E&L to address product quality impacts?

Four Key Considerations When Assessing Components for Annex 1 Readiness

1

Product: Component Specifications​

What are your current component quality specifications for particulates, bioburden and endotoxins? Do they need to be tighter?

2

Process: Manufacturing Design

How will your components and finished drug product be sterilized? How will your components be introduced to the fill/finish line?

3

Protection: Container Closure Integrity

Do you fully understand the multiple factors affecting CCI? What monitoring and testing plan is in place over the drug product shelf life to ensure sterility?

4

Proof: Documentation & Service

Does your supplier have a holistic CCS focused on continual improvement? What documentation is available to support your CCS?

Learn about Annex 1, CCS and CCI From These Resources
Want to Speak with an Annex 1 Expert?

Partner with West’s cutting-edge primary packaging technologies for your complex drug molecules

NovaPure® - Highest quality components trusted by approved molecules Learn More

Image West NovaPure® primary packaging technologies
Mitigate the Risk with Unwanted Stopper Interactions

Mitigate risk as you protect lyo and liquid drugs from visible, subvisible particles and unwanted stopper interactions.

Protect your drug components

Protect your drug with components of superior quality that allow you to choose your preferred/differentiated delivery system.

Optimize syringe performance by reducing plunger variability

Optimize syringe performance by reducing plunger variability and reducing the amount of free silicone oil while maximizing quality.

Learn more about products that can support your EU GMP Annex 1 compliance

Products for EU GMP Annex 1 Compliance

Whether it’s a vial or pre-filled syringe, West has packaging components and systems to help ensure your EU GMP Annex 1 compliance

Services for EU GMP Annex 1 Compliance

West has the analytical services and regulatory support to help ensure your products and manufacturing meet
EU GMP Annex 1 regulations and standards

If you would like to speak to a services and solutions specialist
Other West Products to Help You Ensure GMP Annex 1 Compliance
NovaPure and Flip-Off are registered trademarks of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.
Crystal Zenith and D Sigma are trademarks of Daikyo Seiko, Ltd. and are used under license.
Corning and Valor are registered trademarks of Corning Incorporated.
West Pharmaceutical Services, Inc. is the exclusive distributor of Corning® Valor® vials.